clinical trial · NCT07282587
Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma
Advanced Pheochromocytoma and ParagangliomaPCPGONC206ONC206: Dose 1ONC206: Dose 2
brief summary
This is a two-stage Phase 2 trial evaluating the efficacy and safety of ONC206 in participants with Pheochromocytoma and Paraganglioma (PCPG).
started
Jan 2, 2026
primary completion
Dec 15, 2028
completion
Dec 15, 2028
last updated
Feb 27, 2026
detailed description
Two-Stage Study to evaluate ONC206 as monotherapy doses:
Stage 1: Participants will receive 150mg ONC206 twice daily, on three consecutive days per week (BID TIW) in each 28-day cycle.
* Part A: Initial number of participants will be monitored. * Part B: If a set number of participants have a response, then more participants will be enrolled and treated.
Stage 2: If Stage 1 meets the planned response, the study will proceed, and participants will be randomized 1:1 to receive 1 of 2 ONC206 dose levels.
official title
A Phase 2 Study of ONC206 in Advanced Pheochromocytoma and Paraganglioma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol